Corresponding Author: Katie M. O’Brien, Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709 (obrienkm2@niehs.nih.gov).
Accepted for Publication: November 16, 2019.
Author Contributions: Dr O’Brien had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Joint senior authors: Drs Sandler and Wentzensen.
Concept and design: O'Brien, Tworoger, Sandler, Wentzensen.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: O'Brien, Weinberg, Trabert, Wentzensen.
Critical revision of the manuscript for important intellectual content: O'Brien, Tworoger, Harris, Anderson, Trabert, Kaunitz, D'Aloisio, Sandler, Wentzensen.
Statistical analysis: O'Brien, Tworoger, Harris, Trabert.
Obtained funding: Sandler.
Administrative, technical, or material support: O'Brien, Tworoger, Harris, Kaunitz, D'Aloisio.
Supervision: Sandler, Wentzensen.
Conflict of Interest Disclosures: Dr Tworoger reported receipt of grants from the US Department of Defense Ovarian Cancer Research Program (OCRP) and the National Institutes of Health (NIH) both during the conduct of the study and outside the submitted work. Dr Anderson reported receipt of grants from the National Heart Lung Blood Institute (NHLBI) during the conduct of the study. Dr Kaunitz reported provision of consultancy services to the University of Florida, which receives research funding from companies involved with products related to contraception and treatment of menopausal symptoms; personal fees for consultancy services from Pfizer (injectable contraception), AMAG (treatment of genital atrophy), Mithra (contraceptive and menopausal hormone products), and Merck (implantable and vaginal ring contraception), but no companies involved with sales of powder; royalties from UpToDate; and funding for clinical trials through the University of Florida from Medicines 360 (intrauterine devices), Allergan (treatment of uterine fibroids), Myovant (treatment of uterine fibroids), and Endoceutics (treatment of genital atrophy). No other disclosures were reported.
Funding/Support: This work was supported by the Intramural Research Program of NIH, National Institute of Environmental Health Sciences (Z01-ES044005 to Dr Sandler); the Intramural Research Program of the National Cancer Institute; US Department of Defense OCRP (W81XWH-12-1-0561); NIH (UM1 CA186107, P01 CA87969, UM1 CA176726, and R01 CA67262 [Nurses’ Health Study {NHS} and Nurses’ Health Study II {NHSII}]); NHLBI, NIH/US Department of Health and Human Services (HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C [Women’s Health Initiative Observational Study {WHI-OS}]); and the National Institute of Environmental Health Sciences (Sister Study [SIS]). Dr Harris is supported by an NIH grant (K22 CA193860). Statistical analysis services from Westat (Durham, North Carolina) were provided through a support contract from the National Institute of Environmental Health Sciences with Social and Scientific Systems (Durham, North Carolina).
Role of the Funder/Sponsor: None of the sponsors had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Information: Statistical analyses were replicated by Westat, an independent contractor (Durham, North Carolina).
Additional Contributions: We would like to thank the participants and staff of the participating cohorts for their valuable contributions as well as the following state cancer registries for their help in the NHS/NHSII: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Deleware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentuckyy, Louisiana, Maine, Maryland, Massachusetts, Michigan, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Washington, and Wyoming. The authors acknowledge the Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, as the home of the NHS and the following investigators from the WHI, from the NHLBI, Bethesda, Maryland, Jacques Rossouw, MD, Shari Ludlam, MPH, Joan McGowan, PhD, Leslie Ford, MD, and Nancy Geller, PhD; Fred Hutchinson Cancer Research Center, Seattle, Washington, Garnet Anderson, PhD, Ross Prentice, PhD, Andrea LaCroix, PhD, and Charles Kooperberg, PhD; Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, JoAnn E. Manson, MD, DrPH (); MedStar Health Research Institute/Howard University, Washington, DC, Barbara V. Howard, PhD; Stanford Prevention Research Center, Stanford, California, Marcia L. Stefanick, PhD; The Ohio State University, Columbus, Rebecca Jackson, MD; University of Arizona, Tucson/Phoenix, Cynthia A. Thomson, PhD, RD; University at Buffalo, Buffalo, NY, Jean Wactawski-Wende, PhD; University of Florida, Gainesville/Jacksonville, Marian Limacher, MD; University of Iowa, Iowa City/Davenport, Jennifer Robinson, MD MPH; University of Pittsburgh, Pittsburgh, Pennsylvania, Lewis Kuller, MD, DrPH; Wake Forest University School of Medicine, Winston-Salem, North Carolina, Sally Shumaker, PhD, and Mark Espeland, PhD; and University of Nevada, Reno, Robert Brunner, PhD. None of aforementioned individuals received compensation for their role in this article.
1.World Health Organization International Agency for Research on Cancer.
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Carbon Black, Titanium Dioxide, and Talc; vol 93; 2010.http://publications.iarc.fr/111 Accessed December 10, 2019.
2.International Agency for Research on Cancer.
IARC Monographs: Arsenic, Metals, Fibres, and Dusts; vol 100C; 2012.http://publications.iarc.fr/120 Accessed December 10, 2019.
4.Terry
KL, Karageorgi
S, Shvetsov
YB,
et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. Genital powder use and risk of ovarian cancer: a pooled analysis of 8525 cases and 9859 controls.
Cancer Prev Res (Phila). 2013;6(8):811-821. doi:
10.1158/1940-6207.CAPR-13-0037PubMedGoogle ScholarCrossref 15.Sandler
DP, Hodgson
ME, Deming-Halverson
SL,
et al; Sister Study Research Team. The Sister Study: baseline methods and participant characteristics.
Environ Health Perspect. 2017;125(12):127003. doi:
10.1289/EHP1923PubMedGoogle Scholar 20.Xue
X, Kim
MY, Gaudet
MM,
et al. A comparison of the polytomous logistic regression and joint cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies.
Cancer Epidemiol Biomarkers Prev. 2013;22(2):275-285. doi:
10.1158/1055-9965.EPI-12-1050PubMedGoogle ScholarCrossref